argenex (ARGX) News Today

argenx SE (NASDAQ: ARGX) is trading lower after a mixed clinical update. The primary driver is the discontinuation of a late-stage Sjögren’s disease trial, which outweighed encouraging results from a separate celiac disease program.

• Positive Sentiment: argenx reported that its Phase 2 trial of FB102 in celiac disease met its primary endpoint, with a statistically significant improvement in the ratio of villous height to crypt depth. The company plans to advance the CD122 inhibitor into Phase 3 development, adding potential value to its pipeline. argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
• Positive Sentiment: The celiac results provide the first clinical validation of FB102 following argenx’s acquisition of Forte Biosciences and could support a new growth opportunity beyond its existing Vyvgart franchise. argenx Meets Primary Endpoint in Phase II Celiac Disease Study
• Neutral Sentiment: Reported short interest was listed at zero shares as of October 9, implying no measurable short-selling pressure based on the supplied data. However, the report’s wording that short interest “increased” conflicts with the zero-share figure, reducing its usefulness as a trading signal.
• Negative Sentiment: argenx discontinued the Phase 3 UNITY study of subcutaneous efgartigimod in Sjögren’s disease after an independent monitoring committee determined the trial was futile at interim analysis. The failure removes a major potential indication for Vyvgart and triggered a sharp selloff. Argenx discontinues Vyvgart study in Sjögren’s disease, shares tumble
• Negative Sentiment: Robert W. Baird lowered its price target to $823 from $932 and retained a neutral rating, reflecting increased uncertainty after the trial setback. argenx price target update
• Negative Sentiment: A shareholder-investigation notice was announced following the trial discontinuation, adding a potential legal and headline risk, although no claims or outcome have been established. argenx Investigation Notice